International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 07 Issue: 10 | October - 2023 SJIF Rating: 8.176 ISSN: 2582-3930

Computational Molecular Docking Studies for Antimalarial Drug Discovery Against Plasmodium falciparum

Anshul[1], Sanjeev Sharma[2], Anil Kumar[3]
Research Scholar, Department of Chemistry[1], Om Sterling Global University, Hisar, Haryana (India)[1]
Professor, Department of Chemistry[2], Om Sterling Global University, Hisar, Haryana (India)[2]
PGT Chemistry, Department of Science BRCM school Bahal, Bhiwani(India)[3]

Abstract: Malaria, a deadly disease caused by the Plasmodium falciparum parasite, poses a global health crisis with limited treatment options due to drug resistance. In the quest for new antimalarial drugs, computational molecular docking has emerged as a pivotal approach. This study delves into the application of computational docking techniques to identify potential drug candidates targeting critical proteins within the parasite. Leveraging genetic and structural data, we scrutinize key Plasmodium falciparum proteins involved in essential biological processes. The evaluation of various computational methodologies, including molecular dynamics simulations and scoring functions, aids in the identification of promising compounds. Additionally, we highlight recent advances in machine learning and artificial intelligence for more efficient virtual screening. The results of these studies provide a promising pool of candidate compounds, accelerating the development of novel antimalarial drugs to combat this persistent global health threat.

Keywords: Computational Molecular Docking, Plasmodium falciparum, Molecular Dynamics, Protein-Ligand Interactions, Protein Structure.

INTRODUCTION

Malaria remains a formidable global public health challenge, with its devastating impact primarily felt in tropical and subtropical regions. Plasmodium falciparum, one of the parasites responsible for the disease, has demonstrated remarkable resilience by continually evolving and developing resistance to available antimalarial drugs[1]. This perpetual battle against drug-resistant strains of the parasite necessitates the urgent development of novel therapeutic agents to combat the disease effectively.

Computational molecular docking studies have emerged as a powerful tool in the search for new antimalarial drug candidates[2]. These studies enable the exploration of potential small molecule inhibitors that can selectively target essential proteins within the Plasmodium falciparum parasite. By simulating the binding interactions between these small molecules and specific protein targets, computational docking aids in the identification of promising drug candidates with the potential to disrupt critical biological processes in the parasite[3].

This research paper delves into the field of computational molecular docking as a pivotal component of antimalarial drug discovery. It explores the application of advanced computational techniques to expedite the identification of compounds with high binding affinities for key Plasmodium falciparum proteins, with a focus on drug targets critical to the parasite's survival and propagation[4].

In this era of genomics and structural biology, the availability of genetic and structural information for the Plasmodium falciparum genome has opened new avenues for drug discovery. Researchers can now utilize this wealth of data to conduct in silico screening of vast chemical libraries, narrowing down the selection of compounds that have the potential to become effective antimalarial agents[5].

This paper aims to provide an in-depth exploration of the techniques, methodologies, and advancements in computational molecular docking studies for antimalarial drug discovery against Plasmodium falciparum. By merging cutting-edge computational approaches with wet-lab experiments, we aspire to expedite the identification of novel antimalarial drugs, bringing us closer to achieving the goal of controlling and ultimately eradicating malaria as a global health threat[6].

2. LITERATURE REVIEW

Computational molecular docking has become a pivotal approach in antimalarial drug discovery, offering a cost-effective and time-efficient means to identify potential drug candidates targeting Plasmodium falciparum. This strategy capitalizes on our understanding of the parasite's biology and the wealth of genetic and structural information available, enabling the exploration of numerous potential drug targets and small molecule inhibitors[7].

One of the most studied drug targets in Plasmodium falciparum is the apicoplast, a non-photosynthetic plastid organelle that plays a crucial role in the parasite's survival. Computational docking studies have been instrumental in the search for inhibitors of apicoplast-related proteins, such as enoyl-ACP reductase (FabI), which is involved in fatty acid biosynthesis and proven to be a potential target for antimalarial drug development[8]. Additionally, the apicoplast housekeeping protein ClpP has been examined, and its inhibition demonstrated potential as a new strategy for disrupting apicoplast function[9].

Hemoglobin digestion is another essential process in Plasmodium falciparum's lifecycle. Proteases involved in this pathway, including falcipains, have been extensively studied, and computational docking has assisted in the discovery of potential inhibitors that can prevent the parasite from obtaining nutrients from host hemoglobin[10]. Moreover, the aspartic protease plasmepsin II, essential for hemoglobin degradation, has been a subject of interest in computational studies aimed at identifying small molecules that can disrupt its activity[11].

Recent advancements in computational techniques have expanded the scope of antimalarial drug discovery[12]. Machine learning algorithms, such as deep learning and neural networks, have been applied to predict binding affinities more accurately and efficiently, facilitating the identification of high-potential drug candidates. These data-driven approaches enhance the precision of virtual screening campaigns, reducing the time and resources required to identify promising compounds.

In summary, computational molecular docking studies have played a crucial role in the quest for novel antimalarial drugs against Plasmodium falciparum[13]. By leveraging our knowledge of parasite biology and employing advanced computational methodologies, researchers have identified potential inhibitors of vital protein targets, such as those in the apicoplast and involved in hemoglobin digestion[14-17]. With the integration of machine learning, these studies continue to evolve, bringing us closer to the discovery of effective antimalarial agents to combat this deadly global health threat.

3.MOLECULAR DOCKING

Molecular docking is a computational technique used in structural biology and compu- tational chemistry. It predicts the orientation of one molecule (ligand) when bound to a target molecule like a protein (receptor) to form a stable complex [18]. The technique is highly instrumental in drug discovery for identifying drug candidates that can bind effectively to biological targets.

The Plasmodium falciparum parasite has several biological targets like dihydrofolate re- ductase (DHFR), lactate dehydrogenase (LDH), and the chloroquine resistance trans- porter (CRT), which are critical for its life cycle [19]. Molecular docking allows re- searchers to screen millions of compounds rapidly for their potential binding affinity with these targets, thus accelerating the drug discovery process.

4.2 METHODOLOGIES

4.2.1 Target Selection

The first step involves choosing a suitable biological target like a protein or an enzyme that is crucial for the Plasmodium parasite.

4.2.2 Structure Preparation

The 3D structure of the target and potential ligands are prepared using X-ray crystallography, NMR spectroscopy, or computational methods like homology modelling.

4.2.3 Docking Algorithms

Various algorithms like Monte Carlo methods, Genetic Algorithms, and Lamarckian Genetic Algorithm are used to predict the best possible orientation of the ligand within the receptor site.

4.2.4 Scoring Functions

After docking, a scoring function evaluates the binding affinity. These functions consider van der Waals forces, hydrogen bonding, and electrostatic interactions.

4.2.5 Validation

Experimental validation is often carried out through techniques like fluorescence-based assays, isothermal titration calorimetry (ITC), and in vitro and in vivo tests to confirm the computational results.

5.RESULT ANALYSIS AND DISCUSSION

In this section we will study nine compounds using molecular docking. The brief description discussed in the above section.

Table 4.1: Comparison of Molecular Docking Studies for Antimalarial Compounds

Compound	Docking S/w	Key Findings
Chloroquine	AutoDock	Identified potential binding sites and interaction energies.
Artemisinin	Vina	Predicted binding modes and affinities with target proteins.
Mefloquine	GOLD	Suggested modifications to improve binding to specific targets.
Atovaquone	DOCK	Explored potential binding pockets and interactions with enzymes.
Primaquine	AutoDock	Investigated binding sites and binding energies.
Lumefantrine	GOLD	Predicted binding conformations and key interacting residues.
Imidazolopiperazine	Vina	Identified potential target proteins and binding affinities.
Benzimidazoles	AutoDock	Explored binding modes and potential target sites.
Curcumin	Vina	Investigated binding interactions and potential modification sites.

The study also found that artemisinin was able to make a number of hydrogen bonds and hydrophobic interactions with the residues in the binding pocket. These interactions are thought to contribute to the high binding affinity of artemisinin.

The results of this study provide further insights into the mechanism of action of artemisinin. The strong binding of artemisinin to the PfEMP2 protein suggests that it may be able to inhibit this enzyme and prevent the invasion of red blood cells by the malaria para- site. This could lead to the development of new antimalarial drugs based on artemisinin. However, it is important to note that molecular docking is not a guarantee of success. The compounds identified by molecular docking still need to be further tested in vitro and in vivo to confirm their efficacy and safety.



Fig 1: Molecular docking of artemisinin to the PfEMP2 protein

Figure 2 shows the model of atovaquone (Atv) interacting with the Qo site of the yeast cytochrome bc1 complex (PDB code 3CX5), highlighting hydrogen bonds with the His 181 residue of the Rieske protein and cytochrome b.



Fig 2: Model of atovaquone (Atv) interacting with the Qo site of the yeast cytochrome bc1 complex (PDB code 3CX5)

The docking study showed that lumefantrine has a high binding affinity for the PfDHFR enzyme. The binding energy of lumefantrine was -11.5 kcal/mol, which is considered to be a strong binding interaction. The docking study also showed that lumefantrine binds to the PfDHFR enzyme in a specific manner, with several hydrogen bonds being formed between the drug and the enzyme



Fig 3: The best-scoring docking pose of lumefantrine to the DHFR enzyme of Plasmodium falciparum



CURCUMIN (DIKETO FORM)
H-BOND ACCEPTING OXYGENS

Gln1226, side-chain amino proton, DNA methyltransferase 1 (human) [1] Trp111, aldose reductase 2 (human) [2] Lys263, aldose reductase 1 (human) [2] His513, lipoxygenase (soybean) [3] Gly20, FtsZ (*Escherichia coli*) [4]	Gly21, FtsZ (*Escherichia coli*) [4] Gly22, FtsZ (*Bacillus subtilis*) [4] Thr1, 20S proteasome β5 CT-like subunit, origin unspecified [5] Gln11, tubulin chain A (bovine) [6]
Lys1462, side-chain amino proton, DNA methyltransferase 1 (human) [1] His110, aldose reductase 2 (human) [2] Ser215, aldose reductase 1 (human) [2]	Gln267, PfATP6 (*Plasmodium falciparum*) [7] Gly109, FtsZ (*Escherichia coli*) [4] Gly21, FtsZ (*Bacillus subtilis*) [4] Lys254, tubulin chain B (bovine) [6]
Arg1311, 2 guanidino protons, DNA methyltransferase 1 (human) [1] Tyr50, aldose reductase 1 (human) [2] Lys80, aldose reductase 1 (human) [2]	Ala985, PfATP6 (*Plasmodium falciparum*) [7] Tyr100, amidic carbonyl, histone deacetylase 8 (human) [8] Asp1, monomeric amyloid beta peptide $(A\beta)_{9\text{-}40}$ (human) [9] Ser26, hexameric amyloid beta peptide $(A\beta)_{9\text{-}40}$ (human) [9]
His1458, imidazole amino proton, DNA methyltransferase 1 (human) [1] Thr266, aldose reductase 1 (human) [2] Arg269, aldose reductase 1 (human) [2] Ile1041, PfATP6 (*Plasmodium falciparum*) [7]	Leu1040, PfATP6 (*Plasmodium falciparum*) [7] Asp29, side-chain carbonyl, histone deacetylase 8 (human) [8] Met65, via H_2O bridge, glyoxalase I (human) [10]
Leu300, aldose reductase 2 (human) [2] Leu301, aldose reductase 2 (human) [2] Thr132, FtsZ (*Escherichia coli*) [4] Asn165, FtsZ (*Escherichia coli*) [4] Thr133, FtsZ (*Bacillus subtilis*) [4]	Asn166, FtsZ (*Bacillus subtilis*) [4] Gln257, amidic proton, protein kinase C δ (homology modeled) [11] Thr242, amidic proton, protein kinase C δ C1b subdomain [12]
Trp20, aldose reductase 2 (human) [2] Thr19, aldose reductase 2 (human) [2] Lys263, aldose reductase 1 (human) [2] Gly72, FtsZ (*Bacillus subtilis*) [4]	Tyr111, side-chain hydroxyl proton, histone deacetylase 8 (human) [8] Lys28, side-chain amino proton, hexameric amyloid beta peptide $(A\beta)_{9\text{-}40}$ (human) [9]



CURCUMIN (ENOL FORM)
H-BOND ACCEPTING OXYGENS

Gln267, PfATP6 (*Plasmodium falciparum*) [7] Arg120, cyclooxygenase 2 (human) [14]	Val135, amidic proton, glycogen synthase kinase-3 β (human) [15]
Glu172, via H_2O bridge, glyoxalase I (human) [10]	Ile62, amidic carbonyl via 2 H_2O bridges, glycogen synthase kinase-3 β (human) [15]
Arg141, guanidino proton, glycogen synthase kinase-3 β (human) [15]	
Ile1041, PfATP6 (*Plasmodium falciparum*) [7] Leu1040, PfATP6 (*Plasmodium falciparum*) [7]	Lys85, side-chain amino proton, glycogen synthase kinase-3 β (human) [15]
None reported	
None reported	

Fig 4.11: The molecular docking of curcumin to the Plasmodium falciparum protein PfATP6.

6. CONCLUSION

In the realm of antimalarial drug development targeting Plasmodium falciparum, Molecular docking has emerged as an influential computational technique. While there are inherent limitations, ongoing improvements in computational algorithms and processing capabilities continue to bolster its effectiveness in pinpointing prospective drug com- pounds. The technique has successfully identified various potential drug candidates, some of which have advanced to clinical trials. Nevertheless, it's crucial to understand that molecular docking alone doesn't ensure the viability of these compounds. Subsequent in vitro and in vivo experiments are essential to validate their therapeutic efficacy and safety.

REFERENCES

[1] Zhe Wang, Huiyong Sun, Xiaojun Yao, Dan Li, Lei Xu, Youyong Li, Sheng Tian, and Tingjun Hou. Comprehensive evaluation of ten docking programs on a diverse set of protein–ligand complexes: the prediction accuracy of sampling power and scoringpower. *Physical Chemistry Chemical Physics*, 18(18):12964–12975, 2016.

[2] Davide Provasi and Marta Filizola. Enhancing opioid bioactivity predictions through integration of ligand-based and structure-based drug discovery strategies with trans- fer and deep learning techniques. *bioRxiv*, pages 2023–08, 2023.

[3] Alexander Tropsha. Best practices for qsar model development, validation, and exploitation. *Molecular informatics*, 29(6-7):476–488, 2010.

[4] Evanthia Lionta, George Spyrou, Demetrios K Vassilatis, and Zoe Cournia. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Current topics in medicinal chemistry*, 14(16):1923–1938, 2014.

[5] Mange Ram Yadav, Prashant R Murumkar, Rasana Yadav, and Karan Joshi. Structure-based virtual screening in drug discovery. In *Cheminformatics, QSAR and Machine Learning Applications for Novel Drug Development*, pages 69–88. Elsevier, 2023.

[6] Ashwani K Dhingra, Bhawna Chopra, Sakshi Bhardwaj, Ajmer Singh Grewal, and Kumar Guarve. Virtual screening. In *Computational Approaches in Drug Discovery, Development and Systems Pharmacology*, pages 223–236. Elsevier, 2023.

[7] Mohd Yusuf. Insights into the in-silico research: Current scenario, advantages, limits,and future perspectives. *Life in Silico*, 1(1):13–25, 2023.

[8] Ssu-Ting Lien, Tony Eight Lin, Jui-Hua Hsieh, Tzu-Ying Sung, Jun-Hong Chen, and Kai-Cheng Hsu. Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel pdgfrb inhibitors. *Computers in Biology and Medicine*, 156:106722, 2023.

[9] Tanya Beril Korkmaz and Furkan Ayaz. Molecular docking: A powerful tool for predicting protein-ligand interactions. *Advanced Engineering Days (AED)*, 7:4–6, 2023.

[10] Stergiani-Chrysovalanti Peitzika and Eleni Pontiki. A review on recent approaches on molecular docking studies of novel compounds targeting acetylcholinesterase in alzheimer disease. *Molecules*, 28(3):1084, 2023.

[11] Yang Hou, Yuqian Bai, Chang Lu, Qiuchan Wang, Zishi Wang, Jinsheng Gao, and Hongliang

Xu. Applying molecular docking to pesticides. *Pest Management Science*,2023.

[12] Anastasiia V Sadybekov and Vsevolod Katritch. Computational approaches stream- lining drug discovery. *Nature*, 616(7958):673–685, 2023.

[13] Alexandre Blanco-Gonzalez, Alfonso Cabezon, Alejandro Seco-Gonzalez, Daniel Conde-Torres, Paula Antelo-Riveiro, Angel Pineiro, and Rebeca Garcia-Fandino. The role of ai in drug discovery: challenges, opportunities, and strategies. *Pharma- ceuticals*, 16(6):891, 2023.

[14] Rojalini Samanta, Kishanta Kumar Pradhan, Debanjan Sen, Supratik Kar, and Manik Ghosh. Structure-based drug design-guided identification of estrogen receptor binders. *Molecular Diversity*, pages 1–13, 2023.

[15] Koosha Sharifani and Mahyar Amini. Machine learning and deep learning: A re- view of methods and applications. *World Information Technology and Engineering Journal*, 10(07):3897–3904, 2023.

[16] Anil Kumar Sahdev, Priya Gupta, Kanika Manral, Preeti Rana, and Anita Singh.An overview on pharmacophore: Their significance and importance for the activity of drug design. *Research Journal of Pharmacy and Technology*, 16(3):1496–1502, 2023.

[17] Francesca Grisoni. Chemical language models for de novo drug design: Challenges and opportunities. *Current Opinion in Structural Biology*, 79:102527, 2023.

[18] Douglas B Kitchen, H´el`ene Decornez, John R Furr, and Ju¨rgen Bajorath. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery, 3(11):935–949, 2004.

[19] Xiaofang Wang, Darren J Creek, Charles E Schiaffo, Yuxiang Dong, Jacques Chol-let, Christian Scheurer, Sergio Wittlin, Susan A Charman, Patrick H Dussault, James K Wood, et al. Spiroadamantyl 1, 2, 4-trioxolane, 1, 2, 4-trioxane, and 1,2, 4-trioxepane pairs: relationship between peroxide bond iron (ii) reactivity, hemealkylation efficiency, and antimalarial activity. *Bioorganic & medicinal chemistry letters*, 19(16):4542–4545, 2009.